Accumulating evidence demonstrates that resistance to sunitinib, a first line drug that inhibits tumor angiogenesis, has become a major problem in prolonging survival in advanced RCC.[24] Interestingly, elevated VEGF‐A was one of the hallmarks of sunitinib resistance as shown by paired xenograft (PDX) sequencing in patients with sunitinib‐resistant RCC (GSE76068) (Figure 6H). The gene discussed is VEGFA; the disease is neoplasm.